Table 2.
Cox Regression Analysis for OS and LFS
| Cox regression analysis for OS | ||
|---|---|---|
|
| ||
| Factor | Relative Risk (95% CI) | P |
| Group | ||
| MRD* | 1.0 | |
| UCB | 0.5 (0.2–1.3) | .14 |
| URD:M | 1.6 (0.7–3.3) | .23 |
| URD:MM | 2.5 (1.2–5.1) | .01 |
| Disease Status at HSCT | ||
| CR1 and CR2* | 1.0 | .02 |
| CR3+ | 3.5 (1.2–9.6) | |
| WBC at diagnosis | ||
| <30×109/L* | 1.0 | .01 |
| ≥30×109/L | 1.9 (1.2–3.0) | |
| R/D CMV serostatus | ||
| Negative/negative* | 1.0 | |
| Positive/negative | 1.0 (0.5–1.8) | .95 |
| Negative/positive | 1.2 (0.6–2.7) | .50 |
| Positive/positive | 3.8 (2.0–7.4) | <.01 |
| No. of induction regimens prior to CR | ||
| 1* | 1.0 | |
| ≥2 | 3.5 (1.2–9.6) | .02 |
| Grade II–IV GVHD | ||
| No* | 1.0 | |
| Yes (time dependent) | 0.7 (0.4–1.2) | .17 |
| Cox Regression Analysis—Relapse | ||
|---|---|---|
|
| ||
| Factor | Relative Risk (95% C.I.) | P |
| Group | ||
| RD* | 1.0 | |
| UCB | 0.3 (0.0–2.4) | .28 |
| Unrelated (HLA mm) | 0.0 (0.0–.) | NE |
| Unrelated (HLA match) | 2.3 (0.6–9.5) | .25 |
| R/D CMV serostatus | ||
| Negative/negative* | 1.0 | |
| Positive/negative | 0.7 (0.2–2.6) | .62 |
| Negative/positive | 2.7 (0.8–9.9) | .13 |
| Positive/positive | 8.4 (2.4–28.8) | <.01 |
| Number of induction regimens prior to CR | ||
| 1* | 1.0 | |
| 2+ | 6.6 (1.9–23.1) | <.01 |
| Grade II–IV acute GVHD | ||
| no* | 1.0 | |
| yes (time-dependent) | 0.6 (0.3–1.4) | .24 |
CMV indicates cytomegalovirus; CR, complete remission; OS, overall survival; LFS, leukemia-free survival; GVHD, graft-versus-host disease; MRD, matched related donor; R/D, recipient/donor; UCB, umbilical cord blood; URD:M, unrelated matched donor; URD:MM, unrelated mismatched donor; WBC, white blood cell count.
*
Reference group.